Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.

Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT.

J Gastrointest Oncol. 2017 Dec;8(6):925-935. doi: 10.21037/jgo.2017.09.05.

2.

Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.

Ludwig KF, Du W, Sorrelle NB, Wnuk-Lipinska K, Topalovski M, Toombs JE, Cruz VH, Yabuuchi S, Rajeshkumar NV, Maitra A, Lorens JB, Brekken RA.

Cancer Res. 2018 Jan 1;78(1):246-255. doi: 10.1158/0008-5472.CAN-17-1973. Epub 2017 Nov 27.

PMID:
29180468
3.

The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.

Begum A, Ewachiw T, Jung C, Huang A, Norberg KJ, Marchionni L, McMillan R, Penchev V, Rajeshkumar NV, Maitra A, Wood L, Wang C, Wolfgang C, DeJesus-Acosta A, Laheru D, Shapiro IM, Padval M, Pachter JA, Weaver DT, Rasheed ZA, Matsui W.

PLoS One. 2017 Jul 10;12(7):e0180181. doi: 10.1371/journal.pone.0180181. eCollection 2017.

4.

Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.

Rajeshkumar NV, Yabuuchi S, Pai SG, De Oliveira E, Kamphorst JJ, Rabinowitz JD, Tejero H, Al-Shahrour F, Hidalgo M, Maitra A, Dang CV.

Clin Cancer Res. 2017 Sep 15;23(18):5639-5647. doi: 10.1158/1078-0432.CCR-17-1115. Epub 2017 Jun 13.

5.

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.

Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A, Hidalgo M.

Br J Cancer. 2016 Aug 9;115(4):442-53. doi: 10.1038/bjc.2016.215. Epub 2016 Jul 21.

6.

Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function.

Rajeshkumar NV, Dutta P, Yabuuchi S, de Wilde RF, Martinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK, Hidalgo M, Dang CV, Gillies RJ, Maitra A.

Cancer Res. 2015 Aug 15;75(16):3355-64. doi: 10.1158/0008-5472.CAN-15-0108. Epub 2015 Jun 25.

7.

Apurinic/apyrimidinic endonuclease/redox factor-1 (APE1/Ref-1) redox function negatively regulates NRF2.

Fishel ML, Wu X, Devlin CM, Logsdon DP, Jiang Y, Luo M, He Y, Yu Z, Tong Y, Lipking KP, Maitra A, Rajeshkumar NV, Scandura G, Kelley MR, Ivan M.

J Biol Chem. 2015 Jan 30;290(5):3057-68. doi: 10.1074/jbc.M114.621995. Epub 2014 Dec 9.

8.

Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics.

Kim MS, Zhong Y, Yachida S, Rajeshkumar NV, Abel ML, Marimuthu A, Mudgal K, Hruban RH, Poling JS, Tyner JW, Maitra A, Iacobuzio-Donahue CA, Pandey A.

Mol Cell Proteomics. 2014 Nov;13(11):2803-11. doi: 10.1074/mcp.M114.038547. Epub 2014 Jun 3.

9.

Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.

Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC, Von Hoff DD, Maitra A, Kimmelman AC.

Cancer Discov. 2014 Aug;4(8):905-13. doi: 10.1158/2159-8290.CD-14-0362. Epub 2014 May 29.

10.

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.

Cancer Lett. 2013 Jul 10;335(1):41-51. doi: 10.1016/j.canlet.2013.01.054. Epub 2013 Feb 10.

11.

Conceptual framework for cutting the pancreatic cancer fuel supply.

Le A, Rajeshkumar NV, Maitra A, Dang CV.

Clin Cancer Res. 2012 Aug 15;18(16):4285-90. doi: 10.1158/1078-0432.CCR-12-0041. Review.

12.

The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.

Mizuma M, Rasheed ZA, Yabuuchi S, Omura N, Campbell NR, de Wilde RF, De Oliveira E, Zhang Q, Puig O, Matsui W, Hidalgo M, Maitra A, Rajeshkumar NV.

Mol Cancer Ther. 2012 Sep;11(9):1999-2009. doi: 10.1158/1535-7163.MCT-12-0017. Epub 2012 Jul 2.

13.

A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer.

Rodríguez-Pascual J, Sha P, García-García E, Rajeshkumar NV, De Vicente E, Quijano Y, Cubillo A, Angulo B, Hernando O, Hidalgo M.

Invest New Drugs. 2013 Feb;31(1):14-9. doi: 10.1007/s10637-012-9822-x. Epub 2012 Jun 7.

PMID:
22669334
14.

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.

Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M.

Invest New Drugs. 2012 Dec;30(6):2391-9. doi: 10.1007/s10637-012-9818-6. Epub 2012 May 1.

15.

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M.

J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.

16.

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.

Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD.

Cancer Biol Ther. 2011 Oct 1;12(7):598-609. Epub 2011 Oct 1.

17.

Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M.

Clin Cancer Res. 2011 Sep 1;17(17):5793-800. doi: 10.1158/1078-0432.CCR-11-0341. Epub 2011 Jul 8.

18.

Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth.

Fishel ML, Jiang Y, Rajeshkumar NV, Scandura G, Sinn AL, He Y, Shen C, Jones DR, Pollok KE, Ivan M, Maitra A, Kelley MR.

Mol Cancer Ther. 2011 Sep;10(9):1698-708. doi: 10.1158/1535-7163.MCT-11-0107. Epub 2011 Jun 23.

19.

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer.

Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D.

Mol Cancer Ther. 2011 Aug;10(8):1311-6. doi: 10.1158/1535-7163.MCT-11-0233. Epub 2011 Jun 14.

20.

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M.

Clin Cancer Res. 2011 May 1;17(9):2799-806. doi: 10.1158/1078-0432.CCR-10-2580. Epub 2011 Mar 9.

21.

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M.

Mol Cancer Ther. 2011 Jan;10(1):3-8. doi: 10.1158/1535-7163.MCT-10-0893. Epub 2010 Dec 6.

22.

Tumor-initiating cells are rare in many human tumors.

Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, Pereira K, Karamboulas C, Moghal N, Rajeshkumar NV, Hidalgo M, Tsao M, Ailles L, Waddell TK, Maitra A, Neel BG, Matsui W.

Cell Stem Cell. 2010 Sep 3;7(3):279-82. doi: 10.1016/j.stem.2010.08.009.

23.

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M.

Br J Cancer. 2010 Aug 24;103(5):649-55. doi: 10.1038/sj.bjc.6605819. Epub 2010 Jul 27.

24.

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M.

Mol Cancer Ther. 2010 Sep;9(9):2582-92. doi: 10.1158/1535-7163.MCT-10-0370. Epub 2010 Jul 26.

25.

Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.

Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A, Hidalgo M, Maitra A, Matsui W.

J Natl Cancer Inst. 2010 Mar 3;102(5):340-51. doi: 10.1093/jnci/djp535. Epub 2010 Feb 17.

26.

A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.

Jimeno A, Rubio-Viqueira B, Rajeshkumar NV, Chan A, Solomon A, Hidalgo M.

Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.

27.

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.

Messersmith WA, Rajeshkumar NV, Tan AC, Wang XF, Diesl V, Choe SE, Follettie M, Coughlin C, Boschelli F, Garcia-Garcia E, Lopez-Rios F, Jimeno A, Hidalgo M.

Mol Cancer Ther. 2009 Jun;8(6):1484-93. doi: 10.1158/1535-7163.MCT-09-0075. Epub 2009 Jun 9.

28.

Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.

Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, Warren MV, Walker J, Green TP, Jimeno A, Messersmith WA, Hidalgo M.

Clin Cancer Res. 2009 Jun 15;15(12):4138-46. doi: 10.1158/1078-0432.CCR-08-3021. Epub 2009 Jun 9.

29.

Characterizing DNA methylation patterns in pancreatic cancer genome.

Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M.

Mol Oncol. 2009 Dec;3(5-6):425-38. doi: 10.1016/j.molonc.2009.03.004. Epub 2009 Apr 22.

30.

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.

Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA, Hidalgo M.

Cancer Res. 2008 Apr 15;68(8):2841-9. doi: 10.1158/0008-5472.CAN-07-5200.

31.
32.

Picroliv accelerates epithelialization and angiogenesis in rat wounds.

Singh AK, Sharma A, Warren J, Madhavan S, Steele K, RajeshKumar NV, Thangapazham RL, Sharma SC, Kulshreshtha DK, Gaddipati J, Maheshwari RK.

Planta Med. 2007 Mar;73(3):251-6. Epub 2007 Feb 22.

PMID:
17318779
33.

Homeopathic medicines do not alter growth and gene expression in prostate and breast cancer cells in vitro.

Thangapazham RL, Gaddipati JP, Rajeshkumar NV, Sharma A, Singh AK, Ives JA, Maheshwari RK, Jonas WB.

Integr Cancer Ther. 2006 Dec;5(4):356-61.

PMID:
17101765
34.

Effect of homeopathic treatment on gene expression in Copenhagen rat tumor tissues.

Thangapazham RL, Rajeshkumar NV, Sharma A, Warren J, Singh AK, Ives JA, Gaddipati JP, Maheshwari RK, Jonas WB.

Integr Cancer Ther. 2006 Dec;5(4):350-5.

PMID:
17101764
35.

Can homeopathic treatment slow prostate cancer growth?

Jonas WB, Gaddipati JP, Rajeshkumar NV, Sharma A, Thangapazham RL, Warren J, Singh AK, Ives JA, Olsen C, Mog SR, Maheshwari RK.

Integr Cancer Ther. 2006 Dec;5(4):343-9.

PMID:
17101763
36.

Determination of endothelin antagonist BMS182874 in plasma by high-performance liquid chromatography.

Chavanpatil MD, Rajeshkumar NV, Gulati A.

Pharmazie. 2006 Jun;61(6):525-7.

PMID:
16826972
37.

Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats.

Rai A, Rajeshkumar NV, Gulati A.

Exp Biol Med (Maywood). 2006 Jun;231(6):1120-2.

PMID:
16741060
38.

Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats.

Rajeshkumar NV, Rai A, Gulati A.

Breast Cancer Res Treat. 2005 Dec;94(3):237-47.

PMID:
16244791
39.

ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats.

Rai A, Rajeshkumar NV, Shord S, Gulati A.

J Pharm Pharmacol. 2005 Jul;57(7):869-76.

PMID:
15969946
40.

Protective effect of a polyherbal preparation, Brahma rasayana against tumor growth and lung metastasis in rat prostate model system.

Gaddipati JP, Rajeshkumar NV, Thangapazham RL, Sharma A, Warren J, Mog SR, Singh AK, Maheshwari RK.

J Exp Ther Oncol. 2004 Oct;4(3):203-12.

PMID:
15724840
41.
42.

Low-Dose Cadmium Exposure Reduces Human Prostate Cell Transformation in Culture and Up-Regulates Metallothionein and MT-1G mRNA.

Gaddipati JP, Rajeshkumar NV, Grove JC, Maharaj SV, Centeno JA, Maheshwari RK, Jonas WB.

Nonlinearity Biol Toxicol Med. 2003 Apr;1(2):199-212.

43.
44.

Brain stem GABA receptor functional regulation during rat liver cell proliferation.

Biju MP, Pyroja S, Rajeshkumar NV, Paulose CS.

Neurochem Res. 2002 Sep;27(9):905-10.

PMID:
12396101
45.

Enhanced GABA(B) receptor in neoplastic rat liver: induction of DNA synthesis by baclofen in hepatocyte cultures.

Biju MP, Pyroja S, Rajeshkumar NV, Paulose CS.

J Biochem Mol Biol Biophys. 2002 Jun;6(3):209-14.

PMID:
12186756
46.

Antitumour and anticarcinogenic activity of Phyllanthus amarus extract.

Rajeshkumar NV, Joy KL, Kuttan G, Ramsewak RS, Nair MG, Kuttan R.

J Ethnopharmacol. 2002 Jun;81(1):17-22.

PMID:
12020923
47.

Cancare-a herbal formulation inhibits chemically induced tumours in experimental animals.

Rajeshkumar NV, Kuttan R.

Indian J Exp Biol. 2001 Jul;39(7):654-9.

PMID:
12019758
48.

Hepatic GABA(A) receptor functional regulation during rat liver cell proliferation.

Biju MP, Pyroja S, Rajeshkumar NV, Paulose CS.

Hepatol Res. 2001 Oct;21(2):136-146.

PMID:
11551834
49.
50.

Inhibition of chemical carcinogenesis by berberine in rats and mice.

Anis KV, Rajeshkumar NV, Kuttan R.

J Pharm Pharmacol. 2001 May;53(5):763-8.

PMID:
11370717

Supplemental Content

Loading ...
Support Center